MS4A1
ENSG00000156738
Target class
Ion channel
Chromosome
11
Approved drugs
10
Clinical candidates (approved and in development)
18
- Approved drugs
- 10
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 18
- Chemical probe available
- No
- Target name
- MS4A1
- Gene name
- Membrane spanning 4-domains A1
- Gene symbol
- MS4A1
- Previous gene symbols
- CD20
- Protein name
- B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1) (Bp35) (Leukocyte surface antigen Leu-16) (Membrane-spanning 4-domains subfamily A member 1) (CD antigen CD20)
- B1
- Bp35
- FMC7
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Membrane spanning 4-domains
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 8
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 556.66
- Tissue specificity (Gini)
- 0.955
- Tissue specificity (tau)
- 0.988
- KEGG gene identifiers
- hsa:931
- Protein interaction confidence
- 0.805643
- Protein interaction partners
- 28
- End position
- 60470752
- Start position
- 60455752
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cell membrane
- Lipid-anchor . Note=Constitutively associated with membrane rafts. .
- Plasma membrane
- PubMed 12920111
- PubMed 22615937
- Tissue specificity (tau)
- 0.988393
- Expression inequality (Gini)
- 0.955436
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 556.66
- Spleen
- 267.81
- Small Intestine - Terminal Ileum
- 46.03
- Whole Blood
- 10.68
- Lung
- 3.49
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes556.66
- Spleen267.81
- Small Intestine - Terminal Ileum46.03
- Whole Blood10.68
- Lung3.49
- Esophagus - Mucosa1.43
- Colon - Transverse1.36
- Testis1.1
- Thyroid0.75
- Adipose - Visceral (Omentum)0.72
- Kidney - Cortex0.71
- Liver0.6
- Stomach0.51
- Fallopian Tube0.46
- Prostate0.45
- Artery - Coronary0.42
- Minor Salivary Gland0.41
- Nerve - Tibial0.41
- Vagina0.4
- Kidney - Medulla0.39
- Breast - Mammary Tissue0.38
- Cervix - Endocervix0.37
- Adipose - Subcutaneous0.35
- Cervix - Ectocervix0.32
- Bladder0.28
And 29 more, listed on the interactive page.
- GO:0002115
- GO:0030183
- GO:0042113
- GO:0050853
- GO:0051262
- GO:1902656
- GO:0005576
- GO:0005886
- GO:0009986
- GO:0044853
- GO:0070062
- GO:0005515
- GO:0019865
- GO:0023026
- GO:0042802
Related records
Trials (2,793)
- "MIRO" Molecularly Oriented Immuno-radio-therapy
- [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
- 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
- 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
- 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
- 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
- A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
- A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
- A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
- A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Compassionate Use (CU) Program of Odronextamab
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Drugs (18)
- Epcoritamab B-lymphocyte antigen CD20 binding agent
- FBT-A05 B-lymphocyte antigen CD20 cross-linking agent
- Glofitamab B-lymphocyte antigen CD20 binding agent
- LFB-R603 B-lymphocyte antigen CD20 binding agent
- Mosunetuzumab B-lymphocyte antigen CD20 binding agent
- MT-3724 B-lymphocyte antigen CD20 binding agent
- Obinutuzumab B-lymphocyte antigen CD20 binding agent
- Ocaratuzumab B-lymphocyte antigen CD20 binding agent
- Ocrelizumab B-lymphocyte antigen CD20 binding agent
- Odronextamab B-lymphocyte antigen CD20 binding agent
- Ofatumumab B-lymphocyte antigen CD20 binding agent
- Rituximab B-lymphocyte antigen CD20 binding agent
- Tositumomab B-lymphocyte antigen CD20 binding agent
- Tositumomab 131I B-lymphocyte antigen CD20 binding agent
- TRU-015 B-lymphocyte antigen CD20 binding agent
- Ublituximab B-lymphocyte antigen CD20 binding agent
- Veltuzumab B-lymphocyte antigen CD20 binding agent
- Yttrium Y 90 ibritumomab tiuxetan B-lymphocyte antigen CD20 binding agent